State of Biomedical Innovation Conference
Past Event
On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference. The goal of this conference was to assess U.S. biomedical innovation and discuss policy solutions that ensure the nation remains a world leader. This year, the conference featured an update to last year’s discussion of the drivers of innovation and how best to track them through use of comprehensive metrics. In addition, the conference specifically focused on novel sources and applications of big data in innovation, with senior-level thought leaders from government, academia, industry, patient advocacy, and clinical care present to share their views and recommendations.
Agenda
Innovation in Action
Gabriel Eichler
General Manager, Client Services & Strategic Initiatives - PatientsLikeMe
Dalvir Gill
Chief Executive Officer - TransCelerate BioPharma Inc.
Martin Kohn
Chief Medical Scientist, Care Delivery Systems - Watson Research Center, IBM
Jeffrey M. Trent
President and Research Director - Translational Genomics Research Institute
Establishing Baseline Metrics in Biomedical Innovation
Murray Aitken
Senior Vice President - IMS Health
Ken Kaitin
Director, Tufts Center for the Study of Drug Development, and Professor - Tufts University School of Medicine
Jonathan Leff
Partner - Deerfield Management
Bernard Munos
Founder - InnoThink Center for Research in Biomedical Innovation
Summary and Closing Remarks
Welcome
Creating Novel Sources and Applications of Data through Policy
Janet Woodcock
Director, Center for Drug Evaluation and Research - US Food and Drug Administration
Kathy Hudson
Deputy Director for Science, Outreach, and Policy - National Institutes of Health
Break
Janet Woodcock
Director, Center for Drug Evaluation and Research - US Food and Drug Administration
Kathy Hudson
Deputy Director for Science, Outreach, and Policy - National Institutes of Health
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
If all that’s alleged [regarding Khashoggi] is true, WeWork will be in bed with a regime that has expressed brazen disregard for virtually any norm of international politics. They should tread carefully before accepting a majority stake from a fund that’s in effect a Saudi investment vehicle.